Shots:
- Trial assessed retatrutide vs PBO, alongside lifestyle intervention in T2D adults (n=537) inadequately controlled with diet & exercise alone & mean disease duration of 2.5yrs.; pts started at 2mg QW, with dose escalation at Q4W till assigned doses of 4mg, 9mg, or 12mg are reached
- Trial met its 1EP, showing superior A1C reduction at 40wks., with reductions of 1.7% (4mg), 2% (9mg), & 1.9% (12mg) based on efficacy estimand & 1.7%, 1.9%, & 1.9% based on treatment-regimen estimand vs 0.8%
- Trial showed a weight loss (2EP) of 11.5%, 15.5%, & 16.8% vs 2.5% (efficacy) & 11.5%, 13.9%, & 15.3% vs 2.6% (treatment-regimen), with no plateau observed; Improvements were also seen across key CV risk factors. Full data to be presented at ADA’26, with more retatrutide results expected next year
Ref: Eli Lilly | Image: Eli Lilly | Press Release
Related News: Eli Lilly Reports P-III (TRIUMPH-4) Trial Data on Retatrutide for Weight Management
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
